Tim Rolph and Kitty Yale (Akero)

Up­dat­ed: Akero says pos­i­tive PhI­Ib da­ta buck the gloomy NASH tide, but ques­tions re­main on safe­ty front

In NASH, pos­i­tive read­outs don’t come too of­ten. Yet ac­cord­ing to Akero, to­day is that day.

Akero Ther­a­peu­tics re­port­ed re­sults from its 24-week HAR­MO­NY Phase IIb tri­al bright and ear­ly Tues­day, look­ing at lead can­di­date and ex-Am­gen drug efrux­ifer­min, or EFX, in 128 pa­tients with biop­sy-con­firmed, pre-cir­rhot­ic NASH. And the study met both its pri­ma­ry end­point and mul­ti­ple sec­ondary end­points.

While in­ves­ti­ga­tors al­so flagged some side ef­fects, Akero said the da­ta set it up for a po­ten­tial Phase III tri­al to con­firm the drug’s im­pact on an in­creas­ing­ly preva­lent dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.